Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30794395 | 1.00 | MAPT (0.45) | MAPTALDH1A1KDM4EL3MBTL1ALOX15 | |
| SCHEMBL2434903 | 0.94 | MAPT (0.48) | MAPTALDH1A1KDM4EL3MBTL1ALOX15 | |
| SCHEMBL30794869 | 0.94 | MAPT (0.48) | MAPTALDH1A1KDM4EL3MBTL1ALOX15 | |
| SCHEMBL2434625 | 0.90 | ALDH1A1 (0.50) | MAPTALDH1A1KDM4EL3MBTL1ALOX15 | |
| SCHEMBL2435116 | 0.85 | CNR1 (0.52) | MAPTALDH1A1KDM4EL3MBTL1ALOX15 | |
| SCHEMBL30795862 | 0.85 | CNR1 (0.52) | MAPTALDH1A1KDM4EL3MBTL1ALOX15 | |
| SCHEMBL2438451 | 0.83 | ALDH1A1 (0.48) | MAPTALDH1A1KDM4EL3MBTL1ALOX15 | |
| SCHEMBL2439684 | 0.83 | KCNQ2 (0.60) | MAPTL3MBTL1KCNQ3KCNQ2 | |
| SCHEMBL30794550 | 0.83 | KCNQ2 (0.60) | MAPTL3MBTL1KCNQ3KCNQ2 | |
| SCHEMBL2438382 | 0.80 | MAPT (0.48) | MAPTALDH1A1KDM4EL3MBTL1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1947093-B9 | Substituted morpholine and thiomorpholine derivatives | LUNDBECK & CO AS H (DK) | 2010-03-03 | — | — | EP | claimed |
| EP-1947093-B1 | Substituted morpholine and thiomorpholine derivatives | LUNDBECK & CO AS H (DK) | 2009-09-23 | — | — | EP | claimed |
| US-8012962-B2 | Substituted thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2011-09-06 | — | — | US | disclosed |
| US-7632835-B2 | 2-Cyclopentyl-N-(2-bromo-6-trifluoromethyl-4-(thio)morpholin-4-yl-phenyl)-acetamide; potent openers of the KCNQ family of potassium ion channels; antiepileptic agents; anticonvulsants; anxiolytic agents; neurodegenerative disorders; analgesics for headaches, neuropathic pain; bipolar disorders | H. LUNDBECK A/S (DK) | 2009-12-15 | — | — | US | disclosed |
| US-20090137571-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137571-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | OPRM1, OPRK1, OPRD1 | MAPT 176/4885ALDH1A1 1816/4885KDM4E 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.